Video

Localized Prostate Cancer VL

Search

The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer - Rana R. Mckay Details Rana McKay joins Alicia Morgans to discuss the outcomes of a study investigating randomized patients with high-risk prostate cancer (Gleason ≥4+3, PSA >20, T3 disease, and lymph nodes <20 mm) to either abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) for a total of 6 cycles (each cycle 28 days), followed by radical prostatectomy. A total of...
Active Surveillance for Low-Risk Prostate Cancer - Laurence Klotz and Peter Carroll Details Matt Cooperberg hosts a discussion with Peter Carroll and Laurence Klotz examining their roles in the progress of active surveillance for low-risk prostate cancer and how they incorporate this treatment into clinical practice. They discuss the change in the field from over-detection and overtreatment where radiation and surgery were the primary treatment options to the evolution of active surveill...
Study of Baseline PSA Screening of Men (45 years old) - Peter Albers Details Peter Albers discusses his study of baseline PSA screening of young men across the nation of Germany. The study consists of 45-year-old men who are randomized in two cohorts, one group gets a PSA immediately and the other cohort has a delay of five years. The initial PSA value determines the patient’s risk-adapted strategy and dictates the schedule of further testing. Dr. Albers states that the tr...
Epidemiologic Outcomes of Prostate Cancer Patients Undergoing Active Surveillance - Sigrid Carlsson Details Sigrid Carlsson joins Charles Ryan discussing the epidemiologic outcomes of men in the current era who are facing active surveillance. She reviews the long term data learned from the Memorial Sloan Kettering Cancer Center Experience which mirrors prior reports with low rates of metastasis or cancer-related deaths for patients on active surveillance. They also discuss the migration of pushing the e...
Increasing Rates of Active Surveillance as the Standard of Care in Men with Low Risk Prostate Cancer- Matthew Cooperberg Details Matthew Cooperberg discusses active surveillance as the standard of care for men with low-risk prostate cancer as well as data from multiple registries including CaPSURE, MUSIC, AQUA, and SEER, which report increasing rates of active surveillance in men with low-risk disease. He further discusses the factors that may be driving lower uptake of active surveillance in some practices. Biographies: Ma...
Long-Term Outcomes of Active Surveillance for Prostate Cancer - Interview with Sigrid Carlsson Details Sigrid Carlsson, MD talks with Alicia Morgans, MD about long-term outcomes of active surveillance for prostate cancer, a 17-year experience with active surveillance at the Memorial Sloan Kettering Cancer Center. A study which Carlsson was a co-author on and was presented at the most recent American Urological Association meeting (AUA2018). This was a retrospective analysis of all patients managed...
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons Details J Kellogg Parsons MD, talks with Alicia Morgans prior to his presentation of The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer at the 113th Annual Scientific Meeting of the American Urological Association (AUA) . A much-anticipated presentation of work assessing the feasibility of...